相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1869
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- University of Michigan researchers discovered that removing the amino acid serine from the diet can slow brain tumor growth and make existing treatments more effective in both mouse models and human patients. - The study published in Nature reveals that glioblastoma cells rewire glucose metabolism to fuel growth, relying on blood-derived serine while healthy brain tissue can produce its own serine. - When combined with standard chemoradiation therapy, the serine-restricted diet extended survival in mice by forcing tumor cells to redirect glucose away from DNA repair mechanisms. - Clinical trials are planned to begin later this year or early next year to test the dietary intervention in human glioblastoma patients.
- Michigan Medicine and Materialise initiate an eight-year clinical trial to evaluate 3D-printed bioresorbable airway splints for treating severe tracheobronchomalacia in infants, marking a crucial step toward FDA approval. - The groundbreaking device, successfully used in over 40 emergency cases at U-M Health Mott Children's Hospital, is designed to grow with patients and safely dissolve over time. - The multi-center trial aims to enroll 35 infants across five children's hospitals, with Materialise manufacturing the customized devices at their Ann Arbor facility.
- A new Michigan Medicine survey finds that 67% of adults over 50 who continue working report positive impacts on physical health, with benefits particularly pronounced in those over 65. - Working seniors report significant mental health advantages, with 71% experiencing positive effects and notably higher benefits observed in the 65+ age group compared to those aged 50-64. - Beyond health benefits, 78% of working seniors cite financial stability as a key motivator, while other advantages include maintaining cognitive sharpness, social connections, and sense of purpose.
